Pharma-Bio Serv Declares Substantial Special Dividend Alongside Full-Year Results
PBSV sits 73% above its 52-week low of $0.313.
Summary
Pharma-Bio Serv declared a substantial special dividend of $0.075 per share, a significant capital return, alongside its full-year 2025 results showing a reduced net loss and decreased revenue.
Key Events · Financing and Capital Events · PBSV
-
Special Dividend Declared
The Board of Directors approved a special dividend of $0.075 per share, payable on or about March 20, 2026, to shareholders of record on February 27, 2026. This represents a highly significant capital return to shareholders.
-
Reduced Net Loss
For the year ended October 31, 2025, the company reported a net loss of approximately $0.1 million, an improvement of approximately $0.7 million compared to the prior year.
-
Revenue Decrease
Revenues for the year ended October 31, 2025, were approximately $9.0 million, a decrease of approximately $0.5 million when compared to the previous year.
-
Strategic Alignment
The CEO noted ongoing efforts to strengthen business fundamentals, rationalize the service portfolio, and align the organizational structure with strategic priorities for more consistent performance in 2026.
Analysis · PBSV · Trade & Services
Pharma-Bio Serv, Inc. announced a significant special dividend of $0.075 per share, representing a substantial return to shareholders relative to the company's market capitalization. This capital distribution comes as the company reported its full-year 2025 financial results, which included a reduced net loss and a slight decrease in revenue. The CEO's commentary highlighted strategic efforts to strengthen business fundamentals and align with differentiated markets, aiming for improved performance in 2026. While the financial results were also disclosed in a concurrent 10-K filing, the special dividend is a new and highly material event for investors.
At the time of this filing, PBSV was trading at $0.54 on OTC in the Trade & Services sector, with a market capitalization of approximately $12.4M. The 52-week trading range was $0.31 to $1.36. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.